Cumberland Pharmaceuticals (NASDAQ:CPIX) Upgraded to Hold at Wall Street Zen

Cumberland Pharmaceuticals (NASDAQ:CPIX) was upgraded by investment analysts at Wall Street Zen to a “hold” rating in a research note issued on Saturday.

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Cumberland Pharmaceuticals in a report on Monday, December 29th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock currently has an average rating of “Sell”.

Cumberland Pharmaceuticals Stock Up 2.5%

CPIX opened at $4.95 on Friday. The company has a fifty day moving average of $3.01 and a two-hundred day moving average of $3.20. The stock has a market capitalization of $74.05 million, a price-to-earnings ratio of -20.63 and a beta of -0.53. Cumberland Pharmaceuticals has a fifty-two week low of $1.85 and a fifty-two week high of $7.25. The company has a debt-to-equity ratio of 0.20, a quick ratio of 1.11 and a current ratio of 1.23.

Cumberland Pharmaceuticals (NASDAQ:CPIX) last posted its earnings results on Tuesday, November 4th. The specialty pharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter. Cumberland Pharmaceuticals had a positive return on equity of 5.13% and a negative net margin of 8.06%.The firm had revenue of $8.29 million for the quarter.

Institutional Trading of Cumberland Pharmaceuticals

Several large investors have recently made changes to their positions in the company. Bridgeway Capital Management LLC lifted its holdings in Cumberland Pharmaceuticals by 2.3% in the 2nd quarter. Bridgeway Capital Management LLC now owns 188,355 shares of the specialty pharmaceutical company’s stock valued at $631,000 after purchasing an additional 4,200 shares in the last quarter. Two Sigma Investments LP raised its position in shares of Cumberland Pharmaceuticals by 16.5% in the third quarter. Two Sigma Investments LP now owns 37,591 shares of the specialty pharmaceutical company’s stock valued at $117,000 after buying an additional 5,326 shares during the last quarter. XTX Topco Ltd purchased a new position in shares of Cumberland Pharmaceuticals in the second quarter worth about $34,000. Dimensional Fund Advisors LP boosted its position in Cumberland Pharmaceuticals by 11.1% during the third quarter. Dimensional Fund Advisors LP now owns 280,869 shares of the specialty pharmaceutical company’s stock worth $876,000 after acquiring an additional 27,980 shares during the last quarter. Finally, Heron Bay Capital Management acquired a new position in Cumberland Pharmaceuticals during the second quarter worth about $111,000. 15.51% of the stock is currently owned by hedge funds and other institutional investors.

Cumberland Pharmaceuticals Company Profile

Cumberland Pharmaceuticals Inc (NASDAQ:CPIX) is a specialty pharmaceutical company based in Nashville, Tennessee, focused on the development, manufacture and commercialization of hospital and acute care products. Founded in 1993, the company has built a portfolio of branded therapeutics designed to address critical care needs in emergency medicine, critical care units and other hospital settings. Cumberland’s strategy emphasizes in-licensing and acquiring products that have established safety and efficacy profiles but limited market reach, then leveraging its sales network to expand their commercial footprint.

The company’s flagship products include Acetadote (N-acetylcysteine injection), the only FDA-approved antidote for acetaminophen overdose administered intravenously; Vasostrict (vasopressin injection), used to raise blood pressure in adults with vasodilatory shock; Cerebrex (diclofenac sodium injection), an anti-inflammatory agent for managing acute pain and fever; and Dynastat (parecoxib sodium), a COX-2 inhibitor for postoperative pain relief.